UC Davis Health Begins Trial of Innovative Heart Assist Device

UC Davis Health is at the forefront of medical innovation as one of the first hospitals in the Western United States to participate in the SUPPORT II Pivotal Study.

This clinical trial evaluates the Supira System, a groundbreaking, low-profile percutaneous ventricular assist device (pVAD).

Unlike traditional, bulkier mechanical supports, the Supira System is designed to be smaller, which helps reduce vascular complications and provides cardiologists with better access during complex heart procedures.

By using built-in sensors, the device offers real-time monitoring of pressure, allowing for more precise patient care.

This technology is particularly vital for patients with severe heart disease or those experiencing cardiogenic shock, who require hemodynamic support during life-saving interventions like stenting.

Tai Pham, the UC Davis team is contributing to a larger study involving 385 patients nationwide.

The ultimate goal is to provide safer, more effective options for high-risk patients who were previously deemed ineligible for surgery.

Data from this trial will play a critical role in the FDA approval process, potentially making this technology standard for cardiovascular care across the country in the future.